​

(1) Includes approximately $1.4 million of accrued consideration, including approximately $81,000 of accrued interest, related to the repurchase of assets from uBriGene (Boston) Biosciences, Inc. (“uBriGene”) in 2024. The asset repurchase consisted of purchase consideration of an upfront payment of $0.1 million, and a deferred amount of approximately $1.3 million due twelve months after closing; however, the Company can elect to delay its payment obligation for the deferred amount for additional 6-month periods, upon written notice to uBriGene, if the Company’s net assets are below $20 million. Additionally, beginning in June 2025, the deferred amount began accruing interest at a rate of 5% per annum. In June 2026, the Company’s net assets were below $20 million, and it elected to delay the payment.